Current Updates
RXR Agonists

Connexios presented data on RXR Agonist CNX-013-B2 at the 12th International Conference on Alzheimer's & Parkinson's Diseases, Mar 2015

 

Current Updates
NASH

Article on in vitro screening assay platform for NASH published in Fibrogenesis & Tissue Repair, Jan 2015

Current Updates
RXR Agonists

Connexios presented data on therapeutic action of CNX-013-B2 at the Diabetes and Metabolic Dysfunction (J6) - Keystone Symposia, Jan 2015

Current Updates
T2DM Metabolomics

T2DM Metabolomics article published in Molecular BioSystems, Nov 2014

Click

About us

News & Events

Next GENERATION therapies

About Us

Connexios is a venture-backed company established in 2003. We are building a broad innovative clinical pipeline that aims to address the critical clinical gaps in Type 2 Diabetes and related metabolic diseases. Our expertise in the metabolic diseases space is based on our proprietary Network Biology platform that enables us to link the cellular and molecular events and processes.

more

News & Events

  • 18 MAR RXR agonist CNX-013-B2 has a potential to reduce Aß deposition, increases clearance, along with reduced neuronal death in both N2a cells and astrocytes
  • 09 JAN Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices
more

Next Generation Therapies

We beleive that effective therapies have to engage with dysregulations in cell function and outcomes across different tissues in order to provide a robust therapeutic impact.

This is practically true in case of chronic, systemic and multifactorial diseases like T2D.

more